Assessment of intra- and interobserver reproducibility of rest and cold pressor test-stimulated myocardial blood flow with 13N-ammonia and PET

PurposeWe investigated the intraobserver reproducibility of myocardial blood flow (MBF) measurements with PET at rest and during cold pressor test (CPT), and the interobserver agreement.MethodsTwenty normal volunteers were studied. Using 13N-ammonia, MBF was measured at rest and during CPT and measurement was repeated in a 1-day session (short-term reproducibility; SR). After a follow-up of 2 weeks, MBF was measured again at rest and during CPT and compared with the initial baseline measurement (long-term reproducibility; LR). In addition, adenosine-induced hyperemic MBF increases were assessed.ResultsAssessment of the SR did not show a significant absolute difference in MBF at rest, MBF during CPT or the endothelium-related change in MBF from rest to CPT (ΔMBF) (0.09 ± 0.10, 0.11 ± 0.09, and 0.08 ± 0.05 ml/g/min; p = NS), and they were linearly correlated (r = 0.72, r = 0.76 and r = 0.84; p < 0.0001). Corresponding values for standard error of the estimate (SEE), as indicative for the range of MBF measurement error, were 0.14, 0.14, and 0.09 ml/g/min. The LR yielded relatively higher but non-significant absolute differences in the MBF at rest, MBF during CPT and ΔMBF (0.10 ± 0.10, 0.14 ± 0.10, and 0.19 ± 0.10 ml/g/min; p = NS), and paired MBFs significantly correlated (r = 0.75, r = 0.71, and r = 0.60; p < 0.001). Corresponding SEEs were 0.13, 0.15, and 0.16 ml/g/min. The interobserver analysis yielded a high correlation for MBF at rest, MBF during CPT, and hyperemic MBF (r = 0.96, SEE=0.04; r = 0.78, SEE=0.11; and r = 0.87, SEE=0.28; p < 0.0001, respectively), and also a good interobserver correlation for ΔMBF (r = 0.62, SEE=0.09; p < 0.003).ConclusionShort- and long-term MBF responses to CPT, as an index for endothelium-related coronary vasomotion, can be measured reproducibly with 13N-ammonia PET. In addition, the high interobserver reproducibility for repeat analysis of MBF values suggests the measurements to be largely operator independent.

[1]  H. Schelbert,et al.  Noninvasive Assessment of Coronary Microcirculatory Function in Postmenopausal Women and Effects of Short-Term and Long-Term Estrogen Administration , 2002, Circulation.

[2]  John O. Prior,et al.  Coronary Circulatory Dysfunction in Insulin Resistance, Impaired Glucose Tolerance, and Type 2 Diabetes Mellitus , 2005, Circulation.

[3]  W. Burchert,et al.  Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Cyrill Burger,et al.  Bicycle exercise stress in PET for assessment of coronary flow reserve: repeatability and comparison with adenosine stress. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  T. Lüscher,et al.  Coronary Heart Disease in Smokers: Vitamin C Restores Coronary Microcirculatory Function , 2000, Circulation.

[6]  M. Phelps,et al.  Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. , 1995, Circulation.

[7]  A. Zeiher,et al.  Microvascular dysfunction in angiographically normal or mildly diseased coronary arteries predicts adverse cardiovascular long-term outcome , 2004, Coronary artery disease.

[8]  M. Phelps,et al.  Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  M. Phelps,et al.  Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  H. Schelbert,et al.  Myocardial Blood Flow at Rest and During Pharmacological Vasodilation in Cardiac Transplants During and After Successful Treatment of Rejection , 1994, Circulation.

[11]  John O. Prior,et al.  Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. , 2006, Journal of the American College of Cardiology.

[12]  M. Pfisterer,et al.  Coronary vasoregulation in patients with various risk factors in response to cold pressor testing: contrasting myocardial blood flow responses to short- and long-term vitamin C administration. , 2003, Journal of the American College of Cardiology.

[13]  O. Rimoldi,et al.  Assessment of the long-term reproducibility of baseline and dobutamine-induced myocardial blood flow in patients with stable coronary artery disease. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[15]  John O. Prior,et al.  PET-measured responses of MBF to cold pressor testing correlate with indices of coronary vasomotion on quantitative coronary angiography. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  C. Wyss,et al.  Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  H. Drexler,et al.  Endothelial Dysfunction of the Coronary Microvasculature Is Associated With Impaired Coronary Blood Flow Regulation in Patients With Early Atherosclerosis , 1991, Circulation.

[18]  Robert Elashoff,et al.  Coronary Vasomotor Abnormalities in Insulin-Resistant Individuals , 2004, Annals of Internal Medicine.

[19]  N. Tamaki,et al.  Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  I. Olivotto,et al.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[21]  M. Phelps,et al.  Semiquantitative assessment of myocardial blood flow and viability using polar map displays of cardiac PET images. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  S. Nekolla,et al.  Relation of coronary vasoreactivity and coronary calcification in asymptomatic subjects with a family history of premature coronary artery disease , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  S. Nekolla,et al.  Dysregulation of coronary microvascular reactivity in asymptomatic patients with type 2 diabetes mellitus , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  S. Nekolla,et al.  Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus – a randomized study using positron emission tomography , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[25]  P. Kaufmann,et al.  Myocardial blood flow measurement by PET: technical aspects and clinical applications. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Hatem Alkadhi,et al.  Repeatability of cold pressor test-induced flow increase assessed with H(2)(15)O and PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  A. Zeiher,et al.  Endothelial Function: Cardiac Events , 2005, Circulation.

[28]  S S Gambhir,et al.  Quantification of Regional Myocardial Blood Flow Using 13N‐Ammonia and Reoriented Dynamic Positron Emission Tomographic Imaging , 1992, Circulation.

[29]  D. Kuhl,et al.  N‐13 Ammonia as an Indicator of Myocardial Blood Flow , 1981, Circulation.

[30]  K. Kugiyama,et al.  Endothelial function fluctuates with diurnal variation in the frequency of ischemic episodes in patients with variant angina. , 2002, Journal of the American College of Cardiology.

[31]  A. Drzezga,et al.  Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  J. Yap,et al.  Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  John O. Prior,et al.  PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  J M Bland,et al.  Statistical methods for assessing agreement between two methods of clinical measurement , 1986 .

[35]  John O. Prior,et al.  Determinants of myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  Michael Kreissl,et al.  Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. , 2005, Journal of the American College of Cardiology.

[37]  John O. Prior,et al.  Chronic Inflammation and Impaired Coronary Vasoreactivity in Patients With Coronary Risk Factors , 2004, Circulation.

[38]  E. Hoffman,et al.  Validation of PET-acquired input functions for cardiac studies. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  H. Drexler,et al.  Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. , 1989, Journal of the American College of Cardiology.

[40]  G. Hutchins,et al.  Interobserver and interstudy variability of myocardial blood flow and flow-reserve measurements with nitrogen 13 ammonia-labeled positron emission tomography , 1995, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[41]  John O. Prior,et al.  Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes , 2006, Heart.